Mylan Says Unnamed Inventor Invalidates Merck Vytorin Patent

Law360, Washington (February 05, 2013, 6:15 PM ET) -- Mylan Pharmaceuticals urged a Federal Circuit panel on Tuesday to invalidate Merck Sharp & Dohme Corp. patents covering the cholesterol drug Vytorin, claiming the drugmaker deceived the U.S. Patent and Trademark Office by leaving off a key co-inventor and obfuscating the compound's lineage.

Despite conceding that its application to market a generic version of Vytorin infringed on the two patents-in-suit, Mylan claimed Merck's failure to name one of its senior chemists as the inventor of one of the active ingredients invalidated the patent from the beginning,...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers